A Pore That Folds Shut: How a Selective Inhibitor Silences a Cardiac Potassium Channel

Every heartbeat depends on a precisely timed exchange of ions across cardiac cell membranes, and among the proteins orchestrating this process the potassium channel KCNQ1 plays a decisive role, helping the heart muscle repolarize after each contraction. Mutations that increase its activity are linked to atrial fibrillation and short QT syndrome, a rare but potentially fatal arrhythmia, yet drugs able to block KCNQ1 selectively, sparing related channels in the brain and inner ear, have remained elusive, largely because how inhibitors bind this channel had never been visualized. A study published on October 2, 2026, in Science Advances by researchers at the University of British Columbia and the Polytechnic University of Marche in Ancona, now fills this gap.

Combining cryo-electron microscopy, molecular dynamics simulations, and electrophysiology, the team captured the channel bound to UCL2077, an experimental compound blocking KCNQ1 at picomolar concentrations in an intermediate state of activation but far less potently once the channel is fully activated. The channel consists of four identical subunits arranged like a crown around a central pore; unexpectedly, the inhibitor binds not all four but only two, facing each other, nestling in a side pocket rather than plugging the pore directly. Importantly, this binding bends the S6 helices so that two phenylalanine residues swing into the conduction pathway, causing an allosteric collapse of the pore that narrows and dehydrates the route of potassium ions. Simulations showed that, even without the drug, this configuration arises spontaneously in the intermediate state but not in the fully activated one, which explains the drug’s preference for the former.

The therapeutic interest of these findings lies in the principle of state-dependent inhibition, since a drug preferentially targeting a transient conformation could, in theory, correct pathological overactivity while preserving normal channel function. Unfortunately, several limitations temper this promise: the structures were obtained from the frog channel, in detergent rather than a native membrane, and without KCNE1, the partner protein with which KCNQ1 generates the cardiac current; the intermediate state was stabilized by engineered mutations; the orientation of the nearly symmetric ligand had to be resolved computationally; and UCL2077 is a research tool rather than a clinical candidate.

Several questions therefore remain open, including whether the same binding mode persists in the human channel assembled with KCNE1, whether the collapsed pore reflects a genuine physiological gating state, and whether this pocket can be exploited by drug-like molecules. Each represents an invitation to further research, ideally through structures in lipid environments and studies in cardiac models, so that these structural templates could guide more precise antiarrhythmic therapies.

Source: Kyriakis E, Roscioni A, Eldstrom J, Sastre D, Dou Y, Taddei A, Molinarolo S, Tian M, Maragliano L, Van Petegem F, Fedida D. Structural and kinetic mechanisms of state-dependent potassium channel inhibition. Science Advances 2026;12(40):eaef8456. DOI: 10.1126/sciadv.aef8456 | PMID: 42826183 | PMCID: PMC13632742 (open access, CC BY 4.0)